The goal of this proposal is to demonstrate the importance of the chemokine/chemokine receptor signaling by stromal derived factor 1 alpha (SDF1; also known as CXCL12) and its cognate receptor CXCR4 in rodent models of neuropathic pain. Dysregulated expression chemokine receptors have been linked to hyperexcitability of dorsal root ganglia (DRG) neurons which underlies peripherally-originated neuropathic pain and constitutes a large number of neuropathic pain disorders. The studies described in this application are designed to fill the gap in our understanding of how nerve injury-induced excitatory changes in SDF1/CXCR4 signaling contribute to the persistence of chronic neuropathic pain. Our preliminary data shows that CXCR4 is absent from sensory neurons in the DRG and are generally unresponsive to SDF1. Studies in our lab have shown that injury substantially enhances both levels of CXCR4 transcripts in DRG and sensory neuron expression of CXCR4 in transgenic reporter mice. Further evidence suggests that this injury-mediated modulation of CXCR4 may also contribute to altered neuronal hyperexcitability. In this proposal, we will carry out studies of injury-mediatd effects on pain thresholds and hyperexcitability at the cellular level in DRG neurons using the FDA-approved highly specific CXCR4 receptor antagonist to test the hypotheses that: i) Block of CXCR4 in DRG neurons derived from injured rodents ameliorates pain behavior; ii) Injury alters calcium or sodium currents in CXCR4 responsive nociceptive DRG neurons; iii) Modulation of SDF1/CXCR4 signaling may serve as a molecular switch to a chronic pain state. We will also use molecular and immunological methods, and voltage-clamp and current-clamp recordings to: iv) Assess injury-mediated effects on altered regulation of expression and modulation of CXCR4; and v) Correlate changes at the molecular and cellular levels in injured and adjacent, uninjured DRG neurons to changes in pain thresholds.

Public Health Relevance

Veterans are an especially vulnerable population for experiencing persistent neuropathic pain because of the battlefield injuries which may have a significant adverse impact on quality of life and effective functioning in society. First line therapeutics for neuropathic pain exhibit limited clinical utility and considerable side effects including substance abuse. New targets for the development of well tolerated pain medications that lack abusive qualities are urgently needed. The studies proposed will define the relationship of peripheral nerve injury-induced chemokine signaling in the progression from injury to chronic pain and represent an important step in developing effective treatment for this condition.

Agency
National Institute of Health (NIH)
Institute
Veterans Affairs (VA)
Type
Non-HHS Research Projects (I01)
Project #
5I01BX002209-04
Application #
9280811
Study Section
Neurobiology B (NURB)
Project Start
2014-01-01
Project End
2017-12-31
Budget Start
2017-01-01
Budget End
2017-12-31
Support Year
4
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Rlr VA Medical Center
Department
Type
DUNS #
608434697
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Chen, Xingjuan; Liu, Degang; Zhou, Donghui et al. (2018) Small-molecule CaV?1?CaV? antagonist suppresses neuronal voltage-gated calcium-channel trafficking. Proc Natl Acad Sci U S A 115:E10566-E10575
Allette, Yohance M; Kim, Youngsook; Randolph, Aaron L et al. (2017) Decoy peptide targeted to Toll-IL-1R domain inhibits LPS and TLR4-active metabolite morphine-3 glucuronide sensitization of sensory neurons. Sci Rep 7:3741
Salazar, Tatiana E; Richardson, Matthew R; Beli, Eleni et al. (2017) Electroacupuncture Promotes Central Nervous System-Dependent Release of Mesenchymal Stem Cells. Stem Cells 35:1303-1315
Hiasa, Masahiro; Okui, Tatsuo; Allette, Yohance M et al. (2017) Bone Pain Induced by Multiple Myeloma Is Reduced by Targeting V-ATPase and ASIC3. Cancer Res 77:1283-1295
Xiong, Wenhui; Ping, Xingjie; Ripsch, Matthew S et al. (2017) Enhancing excitatory activity of somatosensory cortex alleviates neuropathic pain through regulating homeostatic plasticity. Sci Rep 7:12743
Xie, Jennifer Y; Chew, Lindsey A; Yang, Xiaofang et al. (2016) Sustained relief of ongoing experimental neuropathic pain by a CRMP2 peptide aptamer with low abuse potential. Pain 157:2124-40
Thinschmidt, Jeffrey S; Colon-Perez, Luis M; Febo, Marcelo et al. (2016) Depressed basal hypothalamic neuronal activity in type-1 diabetic mice is correlated with proinflammatory secretion of HMBG1. Neurosci Lett 615:21-7
Wilson, Natalie M; Ripsch, Matthew S; White, Fletcher A (2016) Impact of Opioid and Nonopioid Drugs on Postsurgical Pain Management in the Rat. Pain Res Treat 2016:8364762
Lahiri, Debomoy K; Maloney, Bryan; Bayon, Baindu L et al. (2016) Transgenerational latent early-life associated regulation unites environment and genetics across generations. Epigenomics 8:373-87
Park, Ki Duk; Yang, Xiao-Fang; Dustrude, Erik T et al. (2015) Chimeric agents derived from the functionalized amino acid, lacosamide, and the ?-aminoamide, safinamide: evaluation of their inhibitory actions on voltage-gated sodium channels, and antiseizure and antinociception activities and comparison with lacosamid ACS Chem Neurosci 6:316-30

Showing the most recent 10 out of 16 publications